文献速递造血干细胞移植与细胞治疗淋巴瘤

人类疱疹病毒6型再激活及疾病在嵌合抗原受体T细胞治疗受者中不常见

Human herpesvirus 6 reactivation and disease are infrequent in chimeric antigen receptor T-cell therapy recipients.
PubMed 文献 · Blood · 2024-01-01

该研究通过前瞻性队列(89例,每周HHV-6B检测至12周)和回顾性分析(626例,12周内血/脑脊液检测)评估CAR-T治疗后HHV-6B再激活及疾病发生率。前瞻性队列中HHV-6B再激活累积发生率为6%(95%CI 2.2-12.5),病毒载量低(中位峰值435拷贝/mL)且无需治疗;回顾性分析中可能HHV-6脑炎累积发生率为0.17%(95%CI 0.02-0.94)。结论认为CAR-T后HHV-6B再激活及疾病不常见,不推荐常规HHV-6监测。

要点

  • 前瞻性队列中HHV-6B再激活累积发生率为6%(95%CI 2.2-12.5),病毒载量低且无需治疗。
  • 回顾性分析中可能HHV-6脑炎累积发生率为0.17%(95%CI 0.02-0.94),症状未经治疗改善。
  • 作者认为CAR-T后HHV-6B再激活及疾病不常见,不推荐常规HHV-6监测。

核心结论

  • CAR-T治疗后HHV-6B再激活及疾病不常见,不推荐常规HHV-6监测。

研究设计与样本

  • 前瞻性研究:89例CAR-T受者,输注后每周HHV-6B检测至12周。
  • 回顾性分析:626例CAR-T受者,输注后12周内检测血液和/或脑脊液HHV-6B。

主要发现

  • 前瞻性队列中HHV-6B再激活8/89例,排除3例染色体整合HHV-6后累积发生率为6%(95%CI 2.2-12.5)。
  • 前瞻性队列中HHV-6B检测为中位峰值435拷贝/mL(四分位距164-979),无需治疗。
  • 回顾性分析中626例里24例因症状驱动行血浆检测,1例检出HHV-6B。
  • 回顾性分析中34例行脑脊液HHV-6检测,1例可能HHV-6脑炎,累积发生率为0.17%(95%CI 0.02-0.94),症状未经治疗改善。

关键数值与推荐

  • 可能HHV-6脑炎累积发生率为0.17%(95%CI 0.02-0.94),基于回顾性分析34例行脑脊液检测的患者。

临床怎么用

  • 作者认为CAR-T后HHV-6B再激活及疾病不常见,不推荐常规HHV-6监测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Human herpesvirus 6B (HHV-6B) reactivation and disease are increasingly reported after chimeric antigen receptor (CAR) T-cell therapy (CARTx). HHV-6 reactivation in the CAR T-cell product was recently reported, raising questions about product and patient management. Because of overlapping manifestations with immune effector cell-associated neurotoxicity syndrome, diagnosing HHV-6B encephalitis is challenging. We provide 2 lines of evidence assessing the incidence and outcomes of HHV-6B after CARTx. First, in a prospective study with weekly HHV-6B testing for up to 12 weeks after infusion, HHV-6B reactivation occurred in 8 of 89 participants; 3 had chromosomally integrated HHV-6 and were excluded, resulting in a cumulative incidence of HHV-6B reactivation of 6% (95% confidence interval [CI], 2.2-12.5). HHV-6B detection was low level (median peak, 435 copies per mL; interquartile range, 164-979) and did not require therapy. Second, we retrospectively analyzed HHV-6B detection in the blood and/or cerebrospinal fluid (CSF) within 12 weeks after infusion in CARTx recipients. Of 626 patients, 24 had symptom-driven plasma testing, with detection in 1. Among 34 patients with CSF HHV-6 testing, 1 patient had possible HHV-6 encephalitis for a cumulative incidence of 0.17% (95% CI, 0.02-0.94), although symptoms improved without treatment. Our data demonstrate that HHV-6B reactivation and disease are infrequent after CARTx. Routine HHV-6 monitoring is not warranted.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kampouri E, Krantz EM, Xie H, et al. Human herpesvirus 6 reactivation and disease are infrequent in chimeric antigen receptor T-cell therapy recipients. Blood. 2024. PMID: 38635788. doi:10.1182/blood.2024024145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。